Sorrento Receives Orders of COVISTIX for Commercial Launch in Brazil
06 déc. 2021 14h41 HE
|
Sorrento Therapeutics, Inc.
Sorrento has received orders from its logistics partner and a large diagnostic laboratory client for official commercial launch of COVISTIX™ COVID-19 Virus Rapid Antigen Detection Test in Brazil. SAN...
Scilex Holding Company, a Sorrento Therapeutics Inc. Subsidiary, and Vickers Vantage Corp I (NASDAQ: VCKA) (“SPAC”) Enter into Letter of Intent for Proposed Business Combination
06 déc. 2021 09h00 HE
|
Sorrento Therapeutics, Inc.
Scilex Holding Company (Scilex) a subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), and Vickers Vantage Corp I (Nasdaq: VCKA) announce signing of a letter of intent for a proposed business...
Sorrento Announces Publication of a Series of Novel SARS-CoV-2 Main Protease (MPRO) Inhibitors for Potential Treatment of COVID-19 Patients Infected With SARS-CoV-2 Variants Of Concern, Including Omicron
05 déc. 2021 14h28 HE
|
Sorrento Therapeutics, Inc.
A representative of novel MPro inhibitor series, MPI8, dually inhibits MPro and cathepsin L, a key viral entry enzyme, with high potency and selectivity.Other analogs of the series have been evaluated...
Dr. Henry Ji to Participate in the CEO Fireside Chat Evercore ISI 4th Annual HealthCONx Conference
30 nov. 2021 09h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming...
Sorrento Publishes an Abivertinib Teaser Entitled “Abivertinib – A Franchise Oral Therapeutic for Cancer, COVID-19 and Autoimmune Diseases”
29 nov. 2021 09h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the publication of a Teaser titled “Abivertinib – a Franchise Oral Therapeutic for...
Sorrento Therapeutics Mexico Executes Contract for Sale of 5 Million COVI-STIX Tests for Mexico Market
22 nov. 2021 14h53 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO and MEXICO CITY, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today its subsidiary, Sorrento Therapeutics Mexico, has executed a...
Sorrento Therapeutics Mexico to Partner with the World Boxing Council for the Screening of COVID-19 of all Convention Attendees with COVI-STIX at the 59th World Boxing Council Convention in Mexico City
12 nov. 2021 15h19 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO and MEXICO CITY, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and the World Boxing Council (“WBC”) announced today that Sorrento’s COVI-STIX...
Sorrento Announces Publication of Significant Positive Pivotal Trial Results of Abivertinib for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in the Peer-Reviewed Journal Clinical Cancer Research
12 nov. 2021 09h00 HE
|
Sorrento Therapeutics, Inc.
Abivertinib is a novel third-generation epidermal growth factor receptor (EGFR) inhibitor that irreversibly targets mutant forms of EGFR and Bruton’s tyrosine kinase (BTK) in advanced NSCLC patients...
Sorrento Awarded California Competes Tax Credit
07 nov. 2021 13h08 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 07, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the California Competes Tax Credit Committee has approved the California...
Sorrento Receives Brazilian Health Regulatory Agency (ANVISA) Approval for COVISTIX™ (COVID-19 Virus Antigen Detection Test) for Brazil
03 nov. 2021 10h06 HE
|
Sorrento Therapeutics, Inc.
COVISTIX now approved for point of care use in symptomatic patients by ANVISA (national agency for approval of food, cosmetics, and medical devices) in Brazil.Commercialization in progress with...